Lapsi Health and eMurmur® Unveil AI Analytics Integration for Keikku 2.0
Partnership Delivers Cardiac Auscultation Accuracy to the World’s First FDA-Cleared AI Scribe Stethoscope
Lapsi Health, the Dutch-American healthtech firm, and eMurmur, the Canadian-Austrian chief in cardiac and pulmonary auscultation AI, introduced a partnership to combine eMurmur’s confirmed Heart AI algorithms into Keikku 2.0, the world’s first FDA-cleared sensible stethoscope with an built-in AI scribe. The collaboration units a brand new normal for diagnostic accuracy and scientific effectivity.
The integration combines eMurmur’s clinically validated FDA-cleared and CE-marked coronary heart murmur detection algorithms (with demonstrated 90% sensitivity and specificity in detecting irregular cardiac murmurs) with Keikku 2.0’s revolutionary multimodal platform. This mixture allows healthcare suppliers to carry out expert-level cardiac auscultation whereas concurrently documenting affected person encounters via AI-driven transcription, essentially remodeling the physician-patient session.
“Collaboration is essential to innovation, and this partnership exemplifies that,” stated Jhonatan Bringas Dimitriades, MD, CEO and Co-Founder of Lapsi Health. “This strategic step positions Keikku as one of the highly effective medical companion instruments. By combining Keikku’s {hardware} and AI scribe with eMurmur’s cardiac analytics, we’re creating one of the succesful medical instruments.”
Andreas Schriefl, PhD, Founder and CEO of eMurmur, stated: “When Keikku integrates with our AI, it turns into important in each care setting. From main care to cardiology, from hospital rounds to telehealth, from pediatrics to adults, this partnership will ship unprecedented diagnostic precision the place it issues most.”
Diana van Stijn, MD, PhD, Chief Medical Officer and Co-Founder at Lapsi Health, added: “eMurmur’s algorithms, linked to Keikku, permit us to ship the very best physician-patient session. This integration advances what clinicians can accomplish throughout a single encounter.”
The partnership leverages each corporations’ strengths: Lapsi Health’s experience in gadget design and AI integration, and eMurmur’s specialization in auscultation analytics validated via scientific trials, together with research at Johns Hopkins University. eMurmur’s AI is FDA-cleared, CE-marked, and hardware-agnostic.
The built-in answer will probably be accessible to Keikku 2.0 customers via a seamless software program replace, with no extra {hardware} required. Healthcare suppliers throughout numerous specialties, together with main care, cardiology, pediatrics, and emergency drugs, will achieve entry to cardiologist-level auscultation insights, enabling earlier detection of structural coronary heart illness and extra knowledgeable scientific decision-making.
The publish Lapsi Health and eMurmur® Unveil AI Analytics Integration for Keikku 2.0 first appeared on AI-Tech Park.
